Infection
Xeruborbactam by Qpex Biopharma for Acinetobacter Infections: Likelihood of Approval
Oct
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Xeruborbactam overview
Xeruborbactam is under development for the treatment of carbapenem-resistant infectious diseases including Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter infections. It is administered by intravenous route. The drug candidate is a combination of QPX7728 and beta lactamase inhibitor. The drug candidate acts by targeting beta lactamase. It was under development for the treatment of MDR/XDR gram-negative infections.
Qpex Biopharma overview
Qpex Biopharma is a biopharmaceutical company that discovers and develops therapies for infectious diseases. It is investigating ORAvance, an oral treatment beta-lactamase inhibitor targeting extended spectrum beta lactamase (ESBL) and carbapenem-resistant enterobacteriaceae (CRE) infections; OMNIvance drug against infections caused due to acinetobacter, pseudomonas, and enterobacteriaceae. The company is also developing QPX9003, a next gen synth polymyxin to treat multidrug-resistant (MDR) pseudomonas and acinetobacter infections. Qpex Biopharma is headquartered in San Diego, California, the US.
For a complete picture of Xeruborbactam’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
